Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 4 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Head & Neck 1

Conditions

Breast Neoplasms 16Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Uterine Cervical Neoplasms 1Solid Tumors Refractory to Standard Therapy 1Solid Tumors 1Solid Tumor, Adult 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Kidney Neoplasms 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1ER+ HER2- Advanced Breast Cancer 1

Interventions

pembrolizumab 15Carboplatin 10Paclitaxel 8Nivolumab 7Bevacizumab 6Gemcitabine 4Fulvestrant 4Cisplatin 4olaparib 3lenvatinib 3abemaciclib 3PM 01183 3Oxaliplatin 3Leucovorin 3Letrozole 3Docetaxel 3AZD5305 3tisotumab vedotin 2spartalizumab 2sarilumab 2sargramostim 2sacituzumab govitecan 2ribociclib 2palbociclib 2epacadostat 2enzalutamide 2dostarlimab 2cemiplimab 2anlotinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Endometrial Neoplasms × palbociclib × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
430 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡